Figure 1.
METTL14 is downregulated and associated with tumor metastasis and prognosis in RCC patients. (A) Global m6A levels across normal, primary RCC, and mRCC cells. (B) mRNA levels of METTL14 in 30 paired RCC tissues from Ruijin hospital. (C) METTL14 expression in primary RCC and mRCC samples in the TCGA-KIRC dataset. (D) METTL14 expression in normal, primary RCC, and mRCC samples in the GSE105261 dataset. (E) Kaplan-Meier analysis of OS stratified by METTL14 expression in the TCGA-KIRC dataset. (F) Western blots of METTL14 protein expression in paired normal (N) and tumor (T) samples from the Ruijin-RCC dataset. (G) Representative images of IHC staining for METTL14 protein in the Ruijin-RCC tissue array. (H) METTL14 protein expression in primary RCC and mRCC in the Ruijin-RCC dataset. (I) Kaplan-Meier analysis of PFS stratified by METTL14 protein expression in the Ruijin-RCC dataset. (J) Uni- and Multi-variate analyses of the TCGA-KIRC cohort. (K) Time-dependent receiver operating characteristic analysis comparing the predictive efficiency of METTL14 level alone and in combination with other clinical variables.